Translational Stroke Research

, Volume 4, Issue 1, pp 104–113 | Cite as

Poised for Success: Implementation of Sound Conditioning Strategies to Promote Endogenous Protective Responses to Stroke in Patients

Original Article


The following perspective represents our summary of questions, ideas, concerns, and recommendations expressed by speakers and discussants at the second Biennial Translational Preconditioning Workshop held in Miami in December 2011.


Preconditioning Stroke Meeting Proceedings Translational stroke Perconditioning Postconditioning Clinical trials Hypoxia Ischemia Neuroprotection 


  1. 1.
    Mergenthaler P, Dirnagl U. Protective conditioning of the brain: expressway or roadblock? The Journal of Physiology. 2011;589(17):4147–55.PubMedCrossRefGoogle Scholar
  2. 2.
    Koch S, Katsnelson M, Dong C, Perez-Pinzon M. Remote ischemic limb preconditioning after subarachnoid hemorrhage. Stroke. 2011;42(5):1387–91.PubMedCrossRefGoogle Scholar
  3. 3.
    Keep M, Elmer E, Fong K, Csiszar K. Intrathecal cyclosporin prolongs survival of late-stage ALS mice. Brain Res. 2001;894:327.PubMedCrossRefGoogle Scholar
  4. 4.
    Zhang Y, Park TS, Gidday JM. Hypoxic preconditioning protects human brain endothelium from ischemic apoptosis by Akt-dependent survivin activation. Americal Journal of Physiology Heart Circulation Physiology. 2007;292(6):H2573–81.CrossRefGoogle Scholar
  5. 5.
    Behl C, Holsboer F. Oxidative stress in the pathogenesis of Alzheimer’s disease and antioxidant neuroprotection. Fortschritte Der Neurologie-Psychiatrie. 1998;66(3):113–21.PubMedCrossRefGoogle Scholar
  6. 6.
    Jensen HA, Loukogeorgakis S, Yannopoulos F, Rimpiläinen E, Petzold A, Tuominen H, et al. Remote ischemic preconditioning protects the brain against injury after hypothermic circulatory arrest/clinical perspective. Circulation. 2011;123(7):714–21.PubMedCrossRefGoogle Scholar
  7. 7.
    Lyden PD, Lees KR, Davis SM. Alteplase for acute stroke revisited: the first 10 years. The Lancet Neurology. 2006;5(9):722.CrossRefGoogle Scholar
  8. 8.
    Fisher M, for the Stroke Therapy Academic Industry Roundtable IV. Enhancing the development and approval of acute stroke therapies: stroke therapy academic industry roundtable. Stroke. 2005;36(8):1808–13.PubMedCrossRefGoogle Scholar
  9. 9.
    Lapchak P, Zhang J, Noble-Haeusslein L. RIGOR guidelines: escalating STAIR and STEPS for effective translational research. Translational Stroke Research. 2012. doi:10.1007/s12975-012-0209-2.
  10. 10.
    Kitano H, Young J, Cheng J, Wang L, Hurn PD, Murphy SJ. Gender-specific response to isoflurane preconditioning in focal cerebral ischemia. Journal of Cerebral Blood Flow & Metabolism. 2007;27:1377–86.CrossRefGoogle Scholar
  11. 11.
    Bickler PE, Fahlman CS. Enhanced hypoxic preconditioning by isoflurane: signaling gene expression and requirement of intracellular Ca2+ and inositol triphosphate receptors. Brain Res. 2010;1340(20434434):86–95.PubMedCrossRefGoogle Scholar
  12. 12.
    Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490(7419):187–91.PubMedCrossRefGoogle Scholar
  13. 13.
    Lefer DJ, Bolli R. Development of an NIH Consortium for PreclinicAl AssESsment of CARdioprotective Therapies (CAESAR): a paradigm shift in studies of infarct size limitation. Journal of Cardiovascular Pharmacology and Therapeutics. 2011;16(3–4):332–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Vahlhaus C, Schulz R, Post H, Rose J, Heusch G. Prevention of ischemic preconditioning only by combined inhibition of protein kinase c and protein tyrosine kinase in pigs. Journal of Molecular and Cellular Cardiology. 1998;30(2):197–209.PubMedCrossRefGoogle Scholar
  15. 15.
    Hoda MN, Siddiqui S, Herberg S, Periyasamy-Thandavan S, Bhatia K, Hafez SS, et al. Remote ischemic perconditioning is effective alone and in combination with intravenous tissue-type plasminogen activator in murine model of embolic stroke. Stroke. 2012;21:2012.Google Scholar
  16. 16.
    Nowak TS, Zhao L. Conditioning studies in focal cerebral ischemia: model selection, physiological monitoring, and other methodological issues. Springer Series in Translational Stroke Research. 2013. doi:10.1007/978-1-4419-9695-4_13.
  17. 17.
    Johnston SC, Johnston SC. Ischemic preconditioning from transient ischemic attacks? Data from the Northern California TIA study. Stroke. 2004;35(11_suppl_1):2680–2.PubMedCrossRefGoogle Scholar
  18. 18.
    Huang DT, Walden H, Duda D, Schulman BA. Ubiquitin-like protein activation. Oncogene. 2004;23(11):1958–71.PubMedCrossRefGoogle Scholar
  19. 19.
    Meller R, Minami M, Cameron JA, Impey S, Chen D, Lan JQ, et al. CREB-mediated Bcl-2 protein expression after ischemic preconditioning. J Cereb Blood Flow Metab. 2005;25:234.PubMedCrossRefGoogle Scholar
  20. 20.
    Stenzel-Poore MP, Stevens SL, Xiong Z, Lessov NS, Harrington CA, Mori M, et al. Effect of ischaemic preconditioning on genomic response to cerebral ischaemia: similarity to neuroprotective strategies in hibernation and hypoxia-tolerant states. The Lancet. 2003;362(9389):1028–37.CrossRefGoogle Scholar
  21. 21.
    McLaughlin BA, Hartnett KA, Erhardt JA, Legos JJ, White RF, Barone FC, et al. Caspase 3 activation is essential for neuroprotection in ischemic preconditioning. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(2):715–20.PubMedCrossRefGoogle Scholar
  22. 22.
    Yellon DM, Dana A. The preconditioning phenomenon: a tool for the scientist or a clinical reality? Circ Res. 2000;87(7):543–50.PubMedCrossRefGoogle Scholar
  23. 23.
    Gidday JM, B.K. McMahan, Y. Zhu. Long-lasting neuroprotection induced in mouse retina by repeated hypoxic preconditioning. Invest Ophthalmol Vis Sci 2003; (Program #2942).Google Scholar
  24. 24.
    Kadiiska MB, Gladen BC, Baird DD, Graham LB, Parker CE, Ames BN, et al. Biomarkers of oxidative stress study III. Effects of the nonsteroidal anti-inflammatory agents indomethacin and meclofenamic acid on measurements of oxidative products of lipids in CCl4 poisoning. Free Radical Biology and Medicine. 2005;38(6):711–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, Parker CE, et al. Biomarkers of oxidative stress study II. Are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radical Biology and Medicine. 2005;38(6):698–710.PubMedCrossRefGoogle Scholar
  26. 26.
    Goldemund D, Mikulik R. Reperfusion therapies for acute ischemic stroke. Current Treatment Options in Neurology. 2010;12(2):155–66.PubMedCrossRefGoogle Scholar
  27. 27.
    Abou-Chebl A. Intra-arterial therapy for acute ischemic stroke. Neurotherapeutics. 2011;8(3):400–13.PubMedCrossRefGoogle Scholar
  28. 28.
    Furlan AJ. Clot retrieval for stroke should be restricted to clinical trials no. Stroke. 2010;41(1):194–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. Stroke. 2011;42(1):227–76.PubMedCrossRefGoogle Scholar
  30. 30.
    Della Morte D, Abete P, Gallucci F, Scaglione A, D'Ambrosio D, Gargiulo G, et al. Transient ischemic attack before nonlacunar ischemic stroke in the elderly. Journal of Stroke and Cerebrovascular Diseases. 2008;17(5):257–62.PubMedCrossRefGoogle Scholar
  31. 31.
    Dirnagl U, Simon RP, Hallenbeck JM. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci. 2003;26(5):248–54.PubMedCrossRefGoogle Scholar
  32. 32.
    Moncayo J, de Freitas GR, Bogousslavsky J, Altieri M, van Melle G. Do transient ischemic attacks have a neuroprotective effect? Neurology. 2000;54(11):2089–94.PubMedCrossRefGoogle Scholar
  33. 33.
    McLaughlin BA, Kirshner H. Wagging the dog-moving closer to features defined by basic scientists, the protection of prodromal transient ischaemic attacks reveals itself. European Journal Of Neurology. 2008;15(8):755–6.PubMedCrossRefGoogle Scholar
  34. 34.
    O'Duffy AE, Bordelon YM, McLaughlin B. Killer proteases and little strokes-how the things that do not kill you make you stronger. Journal of Cerebral Blood Flow and Metabolism. 2007;27(4):655–68.PubMedGoogle Scholar
  35. 35.
    Weih M, Kallenberg K, Bergk A, Dirnagl U, Harms L, Wernecke KD, Kallenberg K, Bergk A, Dirnagl U, Harms L, Wernecke KD, et al. Attenuated stroke severity after prodromal TIA: a role for ischemic tolerance in the brain? Stroke. 1999;30(9):1851–4.PubMedCrossRefGoogle Scholar
  36. 36.
    Wegener S, Gottschalk B, Jovanovic V, Knab R, Fiebach JB, Schellinger PD, et al. Transient ischemic attacks before ischemic stroke: preconditioning the human brain? A multicenter magnetic resonance imaging study. Stroke. 2004;35(3):616–21.PubMedCrossRefGoogle Scholar
  37. 37.
    Kissela BM, Khoury J, Alwell K, Miller R, Ewing I, Kleindorfer D, Kissela BM, Khoury J, Alwell K, Miller R, Ewing I, Kleindorfer D, et al. Long term mortality after ischemic stroke: the effect of diabetes in the greater Cincinnati/Northern Kentucky Stroke Study (GCNKSS). Stroke. 2004;35(1):315.Google Scholar
  38. 38.
    Meyer JS, Xu G, Thornby J, Chowdhury MH, Quach M. Is mild cognitive impairment prodromal for vascular dementia like Alzheimer’s disease? Stroke. 2002;33(8):1981–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Sutherland BA, Minnerup J, Balami JS, Arba F, Buchan AM, Kleinschnitz C. Neuroprotection for ischaemic stroke: translation from the bench to the bedside. International Journal of Stroke. 2012;7(5):407–18.PubMedCrossRefGoogle Scholar
  40. 40.
    Gonzalez NR, Liebeskind DS. Letter by Gonzalez and Liebeskind regarding article, “Remote ischemic limb preconditioning after subarachnoid hemorrhage: a Phase Ib study of safety and feasibility”. Stroke. 2011;42(9):e553.Google Scholar
  41. 41.
    Meng R, Asmaro K, Meng L, Liu Y, Ma C, Xi C, et al. Upper limb ischemic preconditioning prevents recurrent stroke in intracranial arterial stenosis. Neurology. 2012;79(18):1853–61.PubMedCrossRefGoogle Scholar
  42. 42.
    Davies SS, Traustadóttir T, Stock AA, Ye F, Shyr Y, Harman SM, et al. Ischemia/reperfusion unveils impaired capacity of older adults to restrain oxidative insult. Free Radical Biology and Medicine. 2009;47(7):1014–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Zaugg M, Lucchinetti E, Uecker M, Pasch T, Schaub MC. Anaesthetics and cardiac preconditioning. Part I. Signalling and cytoprotective mechanisms. Br J Anaesth. 2003;91(4):551–65.PubMedCrossRefGoogle Scholar
  44. 44.
    de Leciñana MA, Fuentes B, Masjuan J, Simal P, Díaz-Otero F, Reig G, et al. Thrombolytic therapy for acute ischemic stroke after recent transient ischemic attack. International Journal of Stroke. 2012;7(3):213–8.PubMedGoogle Scholar
  45. 45.
    Veighey K, MacAllister RJ. Clinical applications of remote ischemic preconditioning. Cardiology Research and Practice. 2012;2012:9.CrossRefGoogle Scholar
  46. 46.
    Thuny F, Lairez O, Roubille F, Mewton N, Rioufol G, Sportouch C, et al. Post-conditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction. Journal of the American College of Cardiology. 2012;59(24):2175–81.PubMedCrossRefGoogle Scholar
  47. 47.
    Thibault H, Piot C, Staat P, Bontemps L, Sportouch C, Rioufol G, et al. Long-term benefit of postconditioning. Circulation. 2008;117(8):1037–44.PubMedCrossRefGoogle Scholar
  48. 48.
    Botker HE, Kharbanda R, Schmidt MR, Bottcher M, Kaltoft AK, Terkelsen CJ, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet. 2010;375(20189026):727–34.PubMedCrossRefGoogle Scholar
  49. 49.
    Ludman AJ, Yellon DM, Hausenloy DJ. Cardiac preconditioning for ischaemia: lost in translation. Dis Model Mech. 2010;3(1–2):35–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Neurology and Pharmacology, JB Marshall Laboratory for Neurovascular TherapeuticsVanderbilt University School of MedicineNashvilleUSA
  2. 2.Departments of Neurosurgery, Cell Biology & Physiology, and Ophthalmology & Visual SciencesWashington University School of MedicineSt. LouisUSA

Personalised recommendations